Herbalife Skin Clearify Spot Treatment
Natural health product licensed in Canada
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Acide 2-hydroxybenzoïque Source : Acide salicylique | 1.5 % |
Non-medicinal ingredients
Phénoxyéthanol, Aqua, Ethylhexylglycérine, Alcool dénaturé, Extrait de graine de Castanea Sativa, Hexylène Glycol, NA, Caprylyl glycol, silice, Polymère croisé-6 de polyacrylate, Niacinamide, EDTA de sodium, Butylène glycol, Triglycéride caprylique/caprique, Extrait de Physalis Angulata, Gomme de xanthane, Jus de feuilles d'Aloe Barbadensis, Triéthanolamine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Crème | minimum: 1 Tous les jours ; maximum: 3 Tous les jours |
Uses authorised in Canada
For the treatment/management of acne. Helps treat acne pimples (Optional: "and allow skin to heal"). Dries and helps clear up acne pimples (Optional: "and allow skin to heal"). Reduces the number and/or severity of acne pimples (Optional: "and allow skin to heal"). Penetrates pores to control (reduce) acne pimples. Helps keep skin clear of new acne pimples. Helps prevent new acne pimples from forming.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
For external use only. This product may cause irritation, burning, itching, swelling and blistering of the skin. If this occurs, discontinue use. If you develop severe itching, hives, swelling of eyes and mouth, blistering or difficulty breathing, consult a health care professional. Using other topical acne products at the same time or immediately following use of this product may increase dryness or irritation of the skin. If this occurs, only one product should be used unless directed by a health care professional. Do not use on broken skin or on large areas of the skin. Do not use if you have very sensitive skin or if you are allergic/sensitive to any ingredient in the product. Discontinue use if excessive skin irritation develops or increases. If irritation persists or spreads beyond the site of application, consult a health care professional. For more severe cases, and/or if substantial improvement is not apparent within 6-8 weeks, consult a health care professional. When using this product avoid contact with eyes; if contact occurs, rinse thoroughly with water. KEEP OUT OF REACH OF CHILDREN. IF SWALLOWED, CALL A POSION CONTROL CENTRE OR A HEALTH CARE PROFESSIONAL IMMEDIATELY.
Product record
- Other names
- Acne Spot Treatment, Herbalife Skin Spot Treatment, Skin Spot Treatment
- Licence holder
- Herbalife International Luxembourg S.á R.L.
- NPN or DIN-HM
- 80075896
- Status
- Active licence
- Licence date
- 1 March 2017
- Revision date
- Not provided
- Form
- Crème
- Route of administration
- Topique
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80075896
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Herbalife Skin Clearify Spot Treatment (Herbalife International Luxembourg S.á R.L.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80075896-herbalife-skin-clearify-spot-treatment, updated 1 March 2017.